{"TCF dependent signaling in response to WNT": ["PIP5K1B"], "Signaling by the B Cell Receptor (BCR)": ["ORAI1"], "Signalling by NGF": ["ARHGEF7"], "Signaling by ERBB2": ["YES1"], "Signaling by Ligand-Responsive EGFR Variants in Cancer": ["ARHGEF7"], "Signaling by WNT in cancer": ["PIP5K1B"], "Transcription": ["SLBP"], "Signaling by Overexpressed Wild-Type EGFR in Cancer": ["ARHGEF7"], "Diseases of glycosylation": ["CSPG4"], "Biological oxidations": ["NR1H4"], "M Phase": ["GOLGA2"], "Signaling by EGFR": ["ARHGEF7"], "Cytokine Signaling in Immune system": ["YES1"], "misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling": ["PIP5K1B"], "RNF mutants show enhanced WNT signaling and proliferation": ["PIP5K1B"], "XAV939 inhibits tankyrase, stabilizing AXIN": ["PIP5K1B"], "Signaling by EGFRvIII in Cancer": ["ARHGEF7"], "Signaling by EGFR in Cancer": ["ARHGEF7"], "Signaling by Wnt": ["PIP5K1B"], "G alpha (i) signalling events": ["RGS14"]}